0001209191-17-027183.txt : 20170417
0001209191-17-027183.hdr.sgml : 20170417
20170417212405
ACCESSION NUMBER: 0001209191-17-027183
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170413
FILED AS OF DATE: 20170417
DATE AS OF CHANGE: 20170417
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kite Pharma, Inc.
CENTRAL INDEX KEY: 0001510580
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
BUSINESS PHONE: (310) 824-9999
MAIL ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CHAMPSI FARAH
CENTRAL INDEX KEY: 0001198321
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36508
FILM NUMBER: 17765839
MAIL ADDRESS:
STREET 1: ONE EMBARCADERO CENTER SUITE 3700
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-04-13
0
0001510580
Kite Pharma, Inc.
KITE
0001198321
CHAMPSI FARAH
C/O KITE PHARMA, INC.
2225 COLORADO AVENUE
SANTA MONICA
CA
90404
1
0
0
0
Common Stock
2017-04-13
4
S
0
72275
82.39
D
191144
I
See Footnote
Common Stock
2017-04-17
4
S
0
43001
82.48
D
148143
I
See Footnote
Common Stock
2017-04-17
4
S
0
100
83.06
D
148043
I
See Footnote
Common Stock
79152
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $82.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Reflects the disposition by Alta Partners VIII, L.P. ("APVIII") of 1,500,000 shares of the Issuer's common stock in a pro-rata distribution to its limited partners on October 19, 2016. Also reflects the transfer from the reporting person to APVIII of 487 shares of the Issuer's common stock on January 26, 2017 and 975 shares of the Issuer's common stock on March 23, 2017. The reporting person has been awarded certain restricted stock units in her capacity as a director of the Company (the "RSUs"), and she is contractually obligated, as a managing director of APVIII, to transfer to APVIII, for no consideration, all shares of common stock that she receives upon the vesting of the RSUs.
The securities are held of record by APVIII. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. The reporting person is a managing director of APMVIII and exercises shared voting and investment power with respect to the shares owned by APVIII. The reporting person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $83.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Includes 58,998 shares received in a pro-rata distribution from APVIII. In prior reports, the reporting person reported beneficial ownership of all shares of the Issuer's common stock held by APVIII. Also reflects the transfer from the reporting person to APVIII of 487 shares of the Issuer's common stock on January 26, 2017 and 975 shares of the Issuer's common stock on March 23, 2017. The reporting person has been awarded certain RSUs in her capacity as a director of the Company, and she is contractually obligated, as a managing director of APVIII, to transfer to APVIII, for no consideration, all shares of common stock that she receives upon the vesting of the RSUs.
/s/ David M. Tanen, Attorney-in-Fact
2017-04-17